CALEB YOUNGBLOOD: Open Payments
NPI 1235366014 · BERKLEY, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$78,806 in 253 payments from 24 companies in 2025. Trend: 2023 $38,466 · 2024 $45,629 · 2025 $78,806
Speaker / faculty: $50,353Travel & lodging: $17,788Food & beverage: $5,866Consulting: $4,800
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 160 | $74,377 |
| ViiV Healthcare Company | 45 | $3,423 |
| ABBVIE INC. | 10 | $152 |
| Theratechnologies Inc. | 2 | $104 |
| AstraZeneca Pharmaceuticals LP | 5 | $92 |
| Napo Pharmaceuticals Inc | 4 | $82 |
| Merck Sharp & Dohme LLC | 3 | $75 |
| PFIZER INC. | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 2 | $53 |
| Verity Pharmaceuticals Inc. | 2 | $49 |
Products named: Yeztugo, Biktarvy, Descovy, DOVATO, CABENUVA, APRETUDE, VRAYLAR, EGRIFTA.
Industry payments across MI — which companies pay providers there.
